Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma

Detalhes bibliográficos
Autor(a) principal: Gameiro, Andreia
Data de Publicação: 2021
Outros Autores: Almeida, Filipe, Nascimento, Catarina, Correia, Jorge Manuel de Jesus, Ferreira, Fernando
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.5/23406
Resumo: Research Areas: Pharmacology & Pharmacy
id RCAP_87132364e1f3f5faa7c3454c4cc6189d
oai_identifier_str oai:www.repository.utl.pt:10400.5/23406
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinomaFeline mammary carcinomaHER2Tyrosine kinase inhibitorsTargeted therapiesFeline her2 TK mutationsResearch Areas: Pharmacology & PharmacyABSTRACT - Feline mammary carcinoma (FMC) is a common neoplasia in cat, being HER2-positive the most prevalent subtype. In woman’s breast cancer, tyrosine kinase inhibitors (TKi) are used as a therapeutic option, by blocking the phosphorylation of the HER2 tyrosine kinase domain. Moreover, clinical trials demonstrated that TKi produce synergistic antiproliferative effects in combination with mTOR inhibitors, overcoming resistance to therapy. Thus, to uncover new chemotherapeutic strategies for cats, the antiproliferative effects of two TKi (lapatinib and neratinib), and their combination with a mTOR inhibitor (rapamycin), were evaluated in FMC cell lines (CAT-M, FMCp and FMCm) and compared with a human breast cancer cell line (SkBR-3). Results revealed that both TKi induced antiproliferative effects in all feline cell lines, by blocking the phosphorylation of EGFR members and its downstream effectors. Furthermore, combined treatments with rapamycin presented synergetic antiproliferative effects. Additionally, the DNA sequence of the her2 TK domain (exons 18 to 20) was determined in 40 FMC tissue samples, and despite several mutations were found none of them were described as inducing resistance to therapy. Altogether, our results demonstrated that TKi and combined protocols may be useful in the treatment of cats with mammary carcinomas, and that TKi-resistant FMC are rare.MDPIRepositório da Universidade de LisboaGameiro, AndreiaAlmeida, FilipeNascimento, CatarinaCorreia, Jorge Manuel de JesusFerreira, Fernando2022-02-05T23:54:15Z2021-03-062021-03-06T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.5/23406engGameiro A, Almeida F, Nascimento C, Correia J, Ferreira F. 2021. Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma. Pharmaceutics, 13(3):346. Doi: 10.3390/pharmaceutics1303034610.3390/pharmaceutics130303461999-4923info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-06T14:52:58Zoai:www.repository.utl.pt:10400.5/23406Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:07:39.078234Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma
title Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma
spellingShingle Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma
Gameiro, Andreia
Feline mammary carcinoma
HER2
Tyrosine kinase inhibitors
Targeted therapies
Feline her2 TK mutations
title_short Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma
title_full Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma
title_fullStr Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma
title_full_unstemmed Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma
title_sort Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma
author Gameiro, Andreia
author_facet Gameiro, Andreia
Almeida, Filipe
Nascimento, Catarina
Correia, Jorge Manuel de Jesus
Ferreira, Fernando
author_role author
author2 Almeida, Filipe
Nascimento, Catarina
Correia, Jorge Manuel de Jesus
Ferreira, Fernando
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Gameiro, Andreia
Almeida, Filipe
Nascimento, Catarina
Correia, Jorge Manuel de Jesus
Ferreira, Fernando
dc.subject.por.fl_str_mv Feline mammary carcinoma
HER2
Tyrosine kinase inhibitors
Targeted therapies
Feline her2 TK mutations
topic Feline mammary carcinoma
HER2
Tyrosine kinase inhibitors
Targeted therapies
Feline her2 TK mutations
description Research Areas: Pharmacology & Pharmacy
publishDate 2021
dc.date.none.fl_str_mv 2021-03-06
2021-03-06T00:00:00Z
2022-02-05T23:54:15Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.5/23406
url http://hdl.handle.net/10400.5/23406
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Gameiro A, Almeida F, Nascimento C, Correia J, Ferreira F. 2021. Tyrosine kinase inhibitors are promising therapeutic tools for cats with HER2-positive mammary carcinoma. Pharmaceutics, 13(3):346. Doi: 10.3390/pharmaceutics13030346
10.3390/pharmaceutics13030346
1999-4923
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131170984689664

Registros relacionados